Caribou Biosciences to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Caribou Biosciences (Nasdaq: CRBU) said company management will participate in investor conferences in November and December 2025.
Scheduled appearances: 2025 Truist Securities BioPharma Symposium, New York — November 6, 2025, and 8th Annual Evercore Healthcare Conference, Coral Gables, FL — December 2, 2025 with a fireside chat at 8:45–9:05 AM ET. Webcasts and event links will be posted on the company Events page and will be available for at least 30 days after each event.
Positive
- None.
Negative
- None.
News Market Reaction 37 Alerts
On the day this news was published, CRBU gained 0.41%, reflecting a mild positive market reaction. Argus tracked a peak move of +185.9% during that session. Argus tracked a trough of -22.6% from its starting point during tracking. Our momentum scanner triggered 37 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $924K to the company's valuation, bringing the market cap to $226M at that time. Trading volume was exceptionally heavy at 64.0x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences:
- 2025 Truist Securities BioPharma Symposium, New York
November 6, 2025
- 8th Annual Evercore Healthcare Conference, Coral Gables, FL
December 2, 2025 with fireside chat at 8:45-9:05 AM ET
Webcast
For more information and links to webcasts, please visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event.
About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies.
Caribou Biosciences, Inc. contact:
Peggy Vorwald, PhD
media@cariboubio.com
investor.relations@cariboubio.com
FAQ
When will Caribou Biosciences (CRBU) present at the Truist Securities BioPharma Symposium?
What is the date and time of Caribou Biosciences (CRBU) fireside chat at the Evercore Healthcare Conference?
Where can investors watch the Caribou Biosciences (CRBU) conference webcasts?
How long will Caribou Biosciences (CRBU) webcasts remain available after each investor event?
Will Caribou Biosciences (CRBU) provide a webcast for the Truist and Evercore events?
How can shareholders find more information about Caribou Biosciences (CRBU) investor events?
